## Improving outcomes for patients with tuberous sclerosis complex-associated seizures: Integrating new treatment options into existing care pathways



## Disclaimer

- Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions
- The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use
- No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities
- USF Health and touchIME accept no responsibility for errors or omissions







#### **Professor James Wheless**

University of Tennessee Health Science Center, Memphis, TN, USA

#### Professor Katarzyna Kotulska

The Children's Memorial Health Institute, Warsaw, Poland

#### Ms Lisa Moss

Caregiver of a patient with TSC and Vice President, Donor Relations, TSC Alliance, Silver Spring, MD, USA



# **Treatment options for TSC-associated seizures**

## **Pharmacologic options**

### **Anti-seizure medications**

- Vigabatrin (1L for infantile spasms)<sup>1</sup>
- ACTH or prednisolone (add-on)<sup>1</sup>
- Other, e.g. levetiracetam, lamotrigine, lacosamide, cenobamate<sup>2,3</sup>

### **mTOR inhibitors**<sup>1</sup>

For TSC-associated tumours

- Everolimus
- Sirolimus (for LAM)

(for refractory TSC) **Ketogenic, MAD or low** glycaemic index diet<sup>1,4,5</sup> **Surgery**<sup>1</sup> After unsuccessful treatment with three medications Vagus nerve stimulation<sup>1</sup> ന്ന **Cannabidiol**<sup>1</sup> ---If surgery is unsuccessful/not possible

1L, first-line; ACTH, adrenocorticotropic hormone; LAM, lymphangiomyomatosis; MAD, modified Atkins diet; mTOR, mammalian target of rapamycin; TSC, tuberous sclerosis complex. 1. Northrup H, et al. *Pediatr Neurol.* 2021;123:50–66; 2. Schubert-Bast S, Strzelczyk A. *Ther Adv Neurol Disord.* 2021;14:1–22; 3. Perucca E. *Acta Epileptologica.* 2021;3:22; 4. Fang Y, et al. *Front Neurol.* 2022;13:863826; 5. Sharma S, Jain P. *Epilepsy Res Treat.* 2014;2014:404202.



**Nonpharmacologic options**